GSK's long-acting injection beats Truvada in HIV prevention trial

by Reuters
Monday, 18 May 2020 08:46 GMT

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

Image Caption and Rights Information

GlaxoSmithKline said cabotegravir was 69% more effective at preventing HIV infection for gay and bisexual men than pre-exposure prophylaxis (PrEP) pill Truvada

(Reuters) - GlaxoSmithKline (GSK.L) said on Monday an injection every other month of its antiviral drug cabotegravir was shown to be more effective at preventing an HIV infection than taking Gilead’s (GILD.O) Truvada pill every day.

The British drugmaker said the drug trial involving men who have sex with men was stopped early after cabotegravir was found to be 69% more effective than the current standard of care, Truvada.